Posted by Michael Wonder on 22 Jul 2020
Jazz Pharmaceuticals announces U.S. FDA approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy
22 July 2020 - Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.
Jazz Pharmaceuticals today announced that the U.S. FDA approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution on 21 July 2020 for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Xywav is an oxybate product with a unique composition of cations resulting in 92% less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate at the recommended dosage range of 6 to 9 grams.
